Jan P Deroose1, Dirk J Grünhagen1, Johannes H W de Wilt2, Alexander M M Eggermont3, Cornelis Verhoef4. 1. Dept. Surgical Oncology, Erasmus MC-Cancer Institute, Rotterdam, The Netherlands. 2. Dept. Surgical Oncology, Radboud University Nijmegen Medical Center, The Netherlands. 3. Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. 4. Dept. Surgical Oncology, Erasmus MC-Cancer Institute, Rotterdam, The Netherlands. Electronic address: c.verhoef@erasmusmc.nl.
Abstract
BACKGROUND: Tumour necrosis factor-α (TNF) and melphalan based isolated limb perfusion (TM-ILP) is an attractive treatment option for advanced extremity soft tissue sarcomas (STS). This study reports on a 20-year single centre experience and discusses the evolution and changes in methodology since the introduction of TNF in ILP. PATIENTS AND METHODS: We performed 306 TM-ILPs in 275 patients with extremity STS. All patients were candidates for amputation or mutilating surgery in order to achieve local control. Clinical response evaluation consisted of clinical examination and magnetic resonance imaging. To evaluate the importance of TNF-dose, treatment results of two periods (1991-2003 high dose (3-4 mg) TNF; 2003-2012 reduced dose (1-2mg) TNF) were compared. RESULTS: During the study period, more femoral perfusions were done instead of iliac perfusions. Reduction of TNF dose and reduction of total ILP time did not lead to different clinical response rates (70% and 69% for periods 1 and 2 respectively) or different local recurrence rates, but was associated with less local toxicity (23% and 14% for periods 1 and 2 respectively). Hospital stay was significantly reduced during the study period. There was an improved pathological response in the high dose TNF group without consequences for clinical outcome. CONCLUSION: TM-ILP remains a very effective treatment modality for limb threatening extremity STS. Moreover, reduction of dose and the growing experience in ILP led to less local toxicity and shorter hospital stay.
BACKGROUND:Tumour necrosis factor-α (TNF) and melphalan based isolated limb perfusion (TM-ILP) is an attractive treatment option for advanced extremity soft tissue sarcomas (STS). This study reports on a 20-year single centre experience and discusses the evolution and changes in methodology since the introduction of TNF in ILP. PATIENTS AND METHODS: We performed 306 TM-ILPs in 275 patients with extremity STS. All patients were candidates for amputation or mutilating surgery in order to achieve local control. Clinical response evaluation consisted of clinical examination and magnetic resonance imaging. To evaluate the importance of TNF-dose, treatment results of two periods (1991-2003 high dose (3-4 mg) TNF; 2003-2012 reduced dose (1-2mg) TNF) were compared. RESULTS: During the study period, more femoral perfusions were done instead of iliac perfusions. Reduction of TNF dose and reduction of total ILP time did not lead to different clinical response rates (70% and 69% for periods 1 and 2 respectively) or different local recurrence rates, but was associated with less local toxicity (23% and 14% for periods 1 and 2 respectively). Hospital stay was significantly reduced during the study period. There was an improved pathological response in the high dose TNF group without consequences for clinical outcome. CONCLUSION: TM-ILP remains a very effective treatment modality for limb threatening extremity STS. Moreover, reduction of dose and the growing experience in ILP led to less local toxicity and shorter hospital stay.
Authors: Juliane Totzke; Deepak Gurbani; Rene Raphemot; Philip F Hughes; Khaldon Bodoor; David A Carlson; David R Loiselle; Asim K Bera; Liesl S Eibschutz; Marisha M Perkins; Amber L Eubanks; Phillip L Campbell; David A Fox; Kenneth D Westover; Timothy A J Haystead; Emily R Derbyshire Journal: Cell Chem Biol Date: 2017-08-17 Impact factor: 8.116
Authors: Farhad Farzaliyev; Alexander Touma; Georg Taeger; Hans-Ulrich Steinau; Jendrik Hardes; Arne Streitbürger; Lars Erik Podleska Journal: World J Surg Oncol Date: 2020-12-21 Impact factor: 2.754